CytomX receives Nasdaq delisting notice for bid price non-compliance

CytomX Therapeutics, Inc.

Nasdaq notified CytomX on Feb 24, 2025 that common stock bid price stayed below $1.00 for 30 consecutive business days through Feb 21, 2025.
Company has 180 calendar days, until August 25, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.
If not cured by the deadline, CytomX may transfer to Nasdaq Capital Market for an additional 180-day compliance period.
Company will monitor bid price and consider options, but there is no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.